1005 One Year Clinical Experience with the Prismaflex Hf 20 Set in Four Infants

Objective: We present the first clinical report involving use of the Prismaflex (Gambro) with the newly developed Prismaflex HF20 Set in 200 consecutive treatments for patients with end-stage renal disease (ESRD). Patients: Four infants with ESRD (ages of 13, 10, 5, and 25 months, and with a body weight of 9.5 kg, 8.5, 6.5, and 9.5 kg, respectively) were treated with intermittent hemodiafiltration (HDF). All patients received five hour treatments. Treatment monitoring included weight change and fluid balance of patients, the efficacy of treatment, the number of interventions, and machine alarms. Results: We used blood flow rate 50 ml/min, dialysate fluid rate of 1000 ml/h and replacement fluid rates of 500 ml/h. Based on the precision of the Prismaflex scales, desired fluid balance was achieved according to the prescribed weight loss for the patients. The efficacy of treatment was monitored by BUN and creatinine values (55 ± 20 mg/dl and 5.3 ± 1.0 mg/dl, respectively) at start of treatment and their decrease after 4 hours of RRT (21 ± 8 mg/dl and 2.2 ± 0.6 mg/ dl, respectively). At the start of treatment, urea and creatinine clearances were 23.3 ± 7.0 ml/min and 19.1 ± 4.4 ml/min, respectively. No complications during the HDF occurred. Conclusion: This is the first report about the use of the Prismaflex HF20 Set in infants with ESRD. No side effects were detected, treatments were tolerated well in all patients, and adaptation of the flow rates to the infants' needs was good.